--- title: "CITIC International lowered the target price for WuXi XDC to 82 yuan, rating it as \"Buy.\"" type: "News" locale: "en" url: "https://longbridge.com/en/news/280437482.md" description: "CMB International has lowered the target price for WUXI XDC to 82 yuan, maintaining a \"Buy\" rating. It is expected that revenue will grow by 46.7% year-on-year in 2025, with adjusted net profit increasing by 69.9%. As of the end of last year, the backlog of uncompleted orders grew by 50.3% to 1.49 billion USD, and new signed orders increased by 41% to 1.33 billion USD. Management expects revenue growth to exceed 40% in 2026" datetime: "2026-03-25T08:24:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280437482.md) - [en](https://longbridge.com/en/news/280437482.md) - [zh-HK](https://longbridge.com/zh-HK/news/280437482.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/280437482.md) | [繁體中文](https://longbridge.com/zh-HK/news/280437482.md) # CITIC International lowered the target price for WuXi XDC to 82 yuan, rating it as "Buy." CMB International published a research report indicating that WuXi XDC (02268.HK) is expected to achieve a year-on-year revenue growth of 46.7% in 2025, with adjusted net profit attributable to the parent company significantly increasing by 69.9% year-on-year. The company's revenue and adjusted net profit attributable to the parent company in 2025 are projected to be 0.6% higher and 1.6% lower than the bank's forecasts, respectively. The bank noted that as of the end of last year, the backlog grew by 50.3% year-on-year to USD 1.49 billion, and new orders signed during the year increased by 41% year-on-year to USD 1.33 billion, continuing the rapid growth momentum. Based on this, management expects revenue to grow by over 40% year-on-year in 2026, with gross margins at least on par with those in 2025. The bank anticipates that the company's revenue will grow by 36.2%, 31.7%, and 29.9% year-on-year in this year, next year, and 2028, respectively, with adjusted net profit growing by 34.5%, 31.7%, and 32.5% year-on-year for those years. Its target price has been lowered from HKD 88 to HKD 82, maintaining a "Buy" rating ### Related Stocks - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/en/quote/520690.CN.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/en/quote/513120.CN.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/en/quote/588860.CN.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/en/quote/159892.CN.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/en/quote/513700.CN.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/en/quote/159615.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/en/quote/560600.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/en/quote/516820.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/en/quote/513060.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/en/quote/159506.CN.md) - [WUXI XDC (02268.HK)](https://longbridge.com/en/quote/02268.HK.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/en/quote/159859.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/en/quote/588250.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/en/quote/159316.CN.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/en/quote/520880.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/en/quote/159992.CN.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/en/quote/159102.CN.md) ## Related News & Research - [Kintor Pharmaceutical Delays Board Meeting to Approve 2025 Annual Results](https://longbridge.com/en/news/280140223.md) - [Xuanzhu’s Breast Cancer Drug Bireociclib Delivers Strong Phase 3 Results Published in JAMA Oncology](https://longbridge.com/en/news/280309450.md) - [Innovent Biologics Phase 3 STAR Study Shows Efdamrofusp Alfa Effective In NAMD](https://longbridge.com/en/news/280236866.md) - [Novo Nordisk, United Bio-Technology Report Positive Mid-stage Clinical Data for UBT251 in China](https://longbridge.com/en/news/280426128.md) - [Sichuan Biokin says BL-ARC002 for treatment of tumours receives clinical trials approval](https://longbridge.com/en/news/280047658.md)